First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China
Z Yang, Y Zhu, G Xiang, T Hua, J Ni… - Expert review of …, 2021 - Taylor & Francis
Objective: To assess the cost-effectiveness of atezolizumab in combination with carboplatin
plus nab-paclitaxel-based chemotherapy versus chemotherapy alone for first-line treatment …
plus nab-paclitaxel-based chemotherapy versus chemotherapy alone for first-line treatment …
Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients
N Paracha, A Abdulla, KS MacGilchrist - Health and quality of life …, 2018 - Springer
Background Health state utility values (HSUVs) are an important input to economic
evaluations and the choice of HSUV can affect the estimate of relative cost-effectiveness …
evaluations and the choice of HSUV can affect the estimate of relative cost-effectiveness …
First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost …
XM Wan, X Luo, CQ Tan, XH Zeng, YC Zhang… - Cancer, 2019 - Wiley Online Library
Background The IMpower150 trial found that adding atezolizumab to the combination of
bevacizumab and chemotherapy improved survival for patients with metastatic …
bevacizumab and chemotherapy improved survival for patients with metastatic …
[HTML][HTML] Vignette-based utilities: usefulness, limitations, and methodological recommendations
LS Matza, KD Stewart, AJ Lloyd, D Rowen, JE Brazier - Value in Health, 2021 - Elsevier
Health technology assessment agencies often prefer that utilities used to calculate quality-
adjusted life years in cost-utility analyses (CUAs) are derived using standardized methods …
adjusted life years in cost-utility analyses (CUAs) are derived using standardized methods …
Cost-effectiveness of domestic PD-1 inhibitor camrelizumab combined with chemotherapy in the first-line treatment of advanced nonsquamous non–Small-Cell lung …
L Qiao, Z Zhou, X Zeng, C Tan - Frontiers in pharmacology, 2021 - frontiersin.org
Objective: Camrelizumab is the first domestic PD-1inhibitor approved to be combined with
chemotherapy as a first-line therapy for advanced nonsquamous non–small-cell lung cancer …
chemotherapy as a first-line therapy for advanced nonsquamous non–small-cell lung cancer …
Cost-effectiveness analysis of durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer
D Ding, H Hu, S Li, Y Zhu, Y Shi, M Liao, J Liu… - Journal of the National …, 2021 - jnccn.org
Background: In the CASPIAN trial, durvalumab 1 chemotherapy demonstrated significant
improvements in overall survival compared with chemotherapy alone in patients with …
improvements in overall survival compared with chemotherapy alone in patients with …
Serplulimab plus chemotherapy vs chemotherapy for treatment of US and Chinese patients with extensive-stage small-cell lung cancer: a cost-effectiveness analysis …
Background Serplulimab is a potential valuable therapy, while patients, physicians, and
decision-makers are uncertain about the cost-effectiveness of this novel drug and its …
decision-makers are uncertain about the cost-effectiveness of this novel drug and its …
Nivolumab vs pembrolizumab for treatment of US patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a network meta …
R Pei, Y Shi, S Lv, T Dai, F Zhang, S Liu… - JAMA network …, 2021 - jamanetwork.com
Importance Nivolumab and pembrolizumab are approved for treating platinum-refractory
recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Physicians …
recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Physicians …
Cost-effectiveness analysis of sintilimab+ chemotherapy versus camrelizumab+ chemotherapy for the treatment of first-line locally advanced or metastatic …
M Rui, Z Fei, Y Wang, X Zhang, A Ma… - Journal of medical …, 2022 - Taylor & Francis
Background and objective Sintilimab is a selective PD-1 inhibitor with efficacy in advanced
or metastatic nonsquamous non-small-cell lung cancer (NSCLC) patients. This study …
or metastatic nonsquamous non-small-cell lung cancer (NSCLC) patients. This study …
Cost-effectiveness of nivolumab-ipilimumab combination therapy for the treatment of advanced non–small cell lung cancer
PT Courtney, AT Yip, DR Cherry, MA Salans… - JAMA network …, 2021 - jamanetwork.com
Importance Treatment with nivolumab-ipilimumab combination therapy was found to
improve overall survival compared with chemotherapy among patients with advanced non …
improve overall survival compared with chemotherapy among patients with advanced non …